Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low–intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol

References

• Shipp MA, Harrington DP. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G, et al ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197–1205.
   PubMed Web of Science ®Google Scholar
• Verdonck LF, Notenboom A, de Jong DD, et al Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 2007;109:2759–2766.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Project TN-HsLPC. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112–2135.
   PubMed Web of Science ®Google Scholar
• Stansfeld AG, Diebold J, Noel H, et al Updated Kiel classification for lymphomas. Lancet 1988;1:292–293.
   PubMed Web of Science ®Google Scholar
• Jaffe E, Harris N, Stein H, Vardiman J, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2000.
   Google Scholar
• Tilly H, Lepage E, Coiffier B, et al Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003;102:4284–4289.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Therneau T, Grambsch P. Modeling survival data. Extending the Cox model. New York: Springer; 2000.
   Google Scholar
• Gray R. A class of K-sample tests for comparing the cuimulative incidence of a competing risk. Ann Stat 1988;16:1141–1154.
   Web of Science ®Google Scholar
• Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995;13:2916–2923.
   PubMed Web of Science ®Google Scholar
• Lambertenghi Deliliers G, Butti C, Baldini L, et al A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma. Haematologica 1995;80:318–324.
   PubMedGoogle Scholar
• De Lena M, Maiello E, Lorusso V, et al Comparison of CHOP-B vs CEOP-B in ‘poor prognosis’ non-Hodgkin's lymphomas. A randomized trial. Med Oncol Tumor Pharmacother 1989;6:163–169.
   PubMedGoogle Scholar
• Aviles A, Guzman R, Delgado S, Nambo MJ, Garcia EL, Diaz-Maqueo JC. Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma. Am J Hematol 1996;52:275–280.
   PubMed Web of Science ®Google Scholar
• Zuckerman KS, Case DC Jr, Gams RA, Prasthofer EF. Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen. Blood 1993;82:3564–3573.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Zwick C, Zeynalova S, et al Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2008;19:545–552.
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, et al Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol–a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025–3030.
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, et al Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–1295.
   PubMed Web of Science ®Google Scholar
• Read WL, Tierney RM, Page NC, et al Differential prognostic impact of comorbidity. J Clin Oncol 2004;22:3099–3103.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Adomat SA, Krajewski S, et al Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244–251.
   PubMed Web of Science ®Google Scholar
• Hermine O, Haioun C, Lepage E, et al Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996;87:265–272.
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, et al Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications–a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805–812.
   PubMed Web of Science ®Google Scholar
• Morel P, Gaulard P, Gisselbrecht C, et al Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. Ann Oncol 2008;19:560–565.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar